ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sonidegib

Also written as “LDE225”, “Sonidegib Phosphate Capsules” and “LDE225+gemcitabine”.

Its studies are mostly in Medulloblastoma · Carcinoma, Basal Cell · Basal Cell Nevus Syndrome · Breast Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Drug pageSonidegib: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 15, 200916 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis150 open or runningphase 2since Dec 15, 2009Apr 9, 2009none ahead
Jemincareits history only10 open or runningphase 4since Mar 12, 2025Mar 12, 2025none ahead

Also a collaborator on its studies: Sun Pharmaceutical Industries and Zhejiang Hangyu Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 9, 2009First study: phase 1 study in MedulloblastomaFirst studyNCT00880308 · 103 enrolled · United States, Spain, Switzerland and more
  2. Dec 15, 2009Phase 2 study in Carcinoma, Basal CellNCT01033019 · 25 enrolled · Australia, Austria
  3. May 12, 2010Phase 2 study in MedulloblastomaNCT01125800 · 76 enrolled · United States, Australia, Canada and more
  4. Sep 21, 2010Phase 1 study in MedulloblastomaNCT01208831 · 45 enrolled · Hong Kong, Japan, Taiwan
  5. Mar 30, 2011Phase 2 study in Carcinoma, Basal CellNCT01327053 · 230 enrolled · United States, Australia, Belgium and more
  6. May 6, 2011Phase 2 study in Carcinoma, Basal CellNCT01350115 · 10 enrolled · Austria, Belgium, Canada and more
  7. Oct 14, 2011Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT01456676 · 11 enrolled · Canada, France, Germany and more
  8. Dec 5, 2011Phase 1 study in Pancreatic NeoplasmsNCT01487785 · 18 enrolled · United States, Spain, United Kingdom
  9. Apr 10, 2012Phase 1 study in Breast NeoplasmsNCT01576666 · 120 enrolled · United States, Australia, Belgium and more
  10. Oct 11, 2012Phase 2 study in MedulloblastomaNCT01708174 · 22 enrolled · United States, Australia, Brazil and more
  11. Jan 8, 20132 phase 1 studiesNCT01764776, NCT01769768
  12. Feb 6, 2013Phase 2 study in Primary MyelofibrosisNCT01787552 · 50 enrolled · Australia, Belgium, Canada and more
  13. Mar 25, 2013Phase 2 study in Leukemia, Myeloid, AcuteNCT01826214 · 70 enrolled · United States, Australia, Austria and more
  14. Dec 1, 2013Phase 2 study in Basal Cell Nevus SyndromeNCT02002689 · 10 enrolled · United States

TargetBeta

SMO →read by rule
“Smoothened homolog inhibitor”ChEMBL 37, by rule

Other programs on SMO

ProgramCompanyFurthest phaseStudies
taladegibruleEli Lillyphase 211

Studies

All 15 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02002689Basal Cell Nevus Syndrome · United States2TerminatedMar 201510
NCT01826214Leukemia, Myeloid, Acute · United States, Australia, Austria and more2CompletedMay 201570
NCT01787552Primary Myelofibrosis · Australia, Belgium, Canada and more2CompletedApr 10, 201850
NCT01769768Advanced Solid Tumor · United States1CompletedAug 2016114
NCT01764776Normal Hepatic Function · United States, Belgium, Bulgaria and more1CompletedMar 201533
NCT01708174Medulloblastoma · United States, Australia, Brazil and more2CompletedOct 5, 201622
NCT01576666Breast Neoplasms · United States, Australia, Belgium and more1CompletedApr 2015120
NCT01487785Pancreatic Neoplasms · United States, Spain, United Kingdom1CompletedJul 201418
NCT01456676Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Canada, France, Germany and more1CompletedFeb 201411
NCT01350115Carcinoma, Basal Cell · Austria, Belgium, Canada and more2CompletedOct 201210
NCT01327053Carcinoma, Basal Cell · United States, Australia, Belgium and more2CompletedJun 28, 2013230
NCT01208831Medulloblastoma · Hong Kong, Japan, Taiwan1CompletedOct 201345
NCT01125800Medulloblastoma · United States, Australia, Canada and more2CompletedOct 201476
NCT01033019Carcinoma, Basal Cell · Australia, Austria2TerminatedFeb 201125
NCT00880308Medulloblastoma · United States, Spain, Switzerland and more1CompletedJul 2013103

How it is read

Names in the registry

  • “LDE225”, 12 entries
  • “Sonidegib Phosphate Capsules”, 1 entry
  • “LDE225+gemcitabine”, 1 entry
  • “Nilotinib + LDE225”, 1 entry
  • “LDE225 0.75%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.